RA Capital Management 13F holdings, Q3 2013
Holdings as of September 30, 2013 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 31 US equity positions worth $724.5m in its Q3 2013 13F filing. The largest position was DYAX CORP at 9.9% of the reported book, followed by NVAX and ACAD. Against the Q2 2013 filing, it opened 10 new positions, added to 7 and reduced 8 among the top 31 holdings.
What did RA Capital Management own in Q3 2013? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2013 |
|---|---|---|---|---|---|---|---|
| 1 | DYAX CORP | 9.9% | $71.5m | 10,418,379 | -4% | reduced | |
| 2 | NVAX NOVAVAX INC | Healthcare | 9.0% | $65.5m | 20,800,000 | 21% | added |
| 3 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 7.7% | $55.9m | 2,035,510 | -69% | reduced |
| 4 | TXMD THERAPEUTICSMD INC | 6.7% | $48.4m | 16,528,641 | 47% | added | |
| 5 | INSM INSMED INC | Healthcare | 6.4% | $46.6m | 2,983,319 | 23% | added |
| 6 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 6.2% | $44.7m | 4,258,244 | -21% | reduced |
| 7 | ACHILLION PHARMACEUTICALS IN | 6.0% | $43.7m | 14,457,061 | 94% | added | |
| 8 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 5.9% | $42.5m | 5,844,700 | – | new |
| 9 | NEWLINK GENETICS CORP | 4.8% | $34.6m | 1,840,294 | 0% | held | |
| 10 | PROTHENA CORP PLC | 4.6% | $33.3m | 1,646,399 | 231% | added | |
| 11 | XOMA CORP DEL | 4.3% | $31.1m | 6,915,525 | 3% | added | |
| 12 | DERMA SCIENCES INC | 3.4% | $24.7m | 1,994,876 | 0% | held | |
| 13 | SUNESIS PHARMACEUTICALS INC | 3.3% | $24.2m | 4,869,261 | 3% | added | |
| 14 | KERYX BIOPHARMACEUTICALS INC | 3.3% | $24.1m | 2,391,261 | -58% | reduced | |
| 15 | HYPERION THERAPEUTICS INC | 3.3% | $23.6m | 902,858 | 0% | held | |
| 16 | CHEMOCENTRYX INC | 2.3% | $16.9m | 3,045,380 | – | new | |
| 17 | BLUEBIRD BIO INC | 1.7% | $12.6m | 467,418 | – | new | |
| 18 | MYGN MYRIAD GENETICS INC | Healthcare | 1.5% | $10.6m | 450,000 | – | new |
| 19 | OMER OMEROS CORP | 1.4% | $10.3m | 1,055,311 | -64% | reduced | |
| 20 | AMPIO PHARMACEUTICALS INC | 1.4% | $9.9m | 1,325,566 | – | new | |
| 21 | ENZB ENZO BIOCHEM INC | 1.2% | $8.4m | 3,348,029 | 0% | held | |
| 22 | MIRATI THERAPEUTICS INC | 1.2% | $8.4m | 551,723 | – | new | |
| 23 | DYNAVAX TECHNOLOGIES CORP | 1.0% | $7.1m | 6,000,000 | 0% | held | |
| 24 | ONCOGENEX PHARMACEUTICALS IN | 1.0% | $7.1m | 763,332 | -12% | reduced | |
| 25 | PTCT PTC THERAPEUTICS INC | Healthcare | 0.9% | $6.4m | 300,000 | – | new |
| 26 | ARROWHEAD RESH CORP | 0.7% | $5.0m | 879,561 | -72% | reduced | |
| 27 | TGTX TG THERAPEUTICS INC | Healthcare | 0.4% | $3.0m | 600,000 | – | new |
| 28 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 0.3% | $2.0m | 70,000 | – | new |
| 29 | OCERA THERAPEUTICS INC | 0.3% | $1.8m | 215,999 | – | new | |
| 30 | EPIZYME INC | 0.1% | $400.0k | 10,000 | -93% | reduced | |
| 31 | SAVIENT PHARMACEUTICALS INC | 0.0% | $193.0k | 1,000,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.